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Abstract: The impact of corticosteroid withdrawal on medium-term graft histological changes in kid-
ney transplant (KT) recipients under standard immunosuppression is uncertain. As part of an open-
label, multicenter, prospective, phase IV, 24-month clinical trial (ClinicalTrials.gov, NCT02284464)
in low-immunological-risk KT recipients, 105 patients were randomized, after a protocol-biopsy at
3 months, to corticosteroid continuation (CSC, n = 52) or corticosteroid withdrawal (CSW, n = 53).
Both groups received tacrolimus and MMF and had another protocol-biopsy at 24 months. The
acute rejection rate, including subclinical inflammation (SCI), was comparable between groups
(21.2 vs. 24.5%). No patients developed dnDSA. Inflammatory and chronicity scores increased from 3
to 24 months in patients with, at baseline, no inflammation (NI) or SCI, regardless of treatment. CSW
patients with SCI at 3 months had a significantly increased chronicity score at 24 months. HbA1c
levels were lower in CSW patients (6.4 ± 1.2 vs. 5.7 ± 0.6%; p = 0.013) at 24 months, as was systolic
blood pressure (134.2 ± 14.9 vs. 125.7 ± 15.3 mmHg; p = 0.016). Allograft function was comparable
between groups and no patients died or lost their graft. An increase in chronicity scores at 2-years
post-transplantation was observed in low-immunological-risk KT recipients with initial NI or SCI,
but CSW may accelerate chronicity changes, especially in patients with early SCI. This strategy did,
however, improve the cardiovascular profiles of patients.
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1. Introduction
Corticosteroids (CS) have long been the mainstay of immunosuppression in solid
organ transplantation, including kidney transplantation (KT), but their long-term use has
been associated with life-threatening complications [1]. Accordingly, strategies to minimize
or withdraw CS have been used in KT recipients [2]. However, therapeutic regimens
involving rapid discontinuation or avoidance of CS can increase the risk of acute rejection,
but there is no clear evidence to support the fact that this therapeutic strategy could have a
detrimental effect on graft survival, especially when corticosteroid withdrawal (CSW) is
carried out in low-to-moderate-immune risk KT recipients using tacrolimus (TAC) plus
mycophenolate mofetil (MMF) [3,4].
Low-grade graft inflammation not qualifying as rejection according to revised Banff
criteria [5], i.e., subclinical inflammation (SCI) or borderline lesions (BL), is very common
post-transplantation, but its clinical impact on long-term KT outcomes is uncertain, and
consensus guidelines and randomized clinical trials are lacking [6–10]. Additionally, the
effect of persistent degrees of low-grade inflammation on KT outcomes after CSW remains
poorly explored, given the current shortage of post-transplant protocol-biopsy information
in controlled clinical trials under TAC-based immunosuppression [6,11–13].
We undertook a randomized controlled study in low-immunological-risk KT recipients
to assess the impact of CSW 3-months post-transplant on inflammatory, especially BL, and
chronic histological changes during the first two years post-transplantation. Additionally,




This study is part of an investigator-driven, parallel-group, open-label, multicenter,
prospective, randomized phase IV clinical trial of 24-months duration (between February
2015 and December 2019) undertaken in low-immunological-risk KT recipients, defined
by a pre-transplant panel-reactive antibody < 25% and absence of de novo donor-specific
antibodies (dnDSA) (ClinicalTrials.gov, number NCT02284464). Figure 1 shows the study
design timeline. A total of 105 Caucasian KT patients aged ≥18 years from 5 Spanish
transplant centers, located in Malaga, Tenerife and Barcelona, were studied. The patients
underwent a protocol biopsy, 3-months post-KT, immediately prior to randomization
according to the previously described study design, and at 24-months post-transplantation.
No patient had either biopsy-proven T-cell-mediated rejection (TCMR) ≥ Banff 1A or acute
antibody-mediated rejection (ABMR) during the first three months post-KT, including at
the time of the third-month protocol biopsy. Thus, patients with no inflammation or SCI
(<Banff 1A) were randomized. Additionally, all had stable graft function, defined as a
serum creatinine < 0.3 mg/dL above the lowest outpatient creatinine, as well as absence of
dnDSA at the time of the protocol biopsy, using a MFI cut-off level of 500 U (One Lambda
LAB screen single antigen bead assay). Finally, patients with proteinuria >1 g/day and
impaired allograft function (serum creatinine > 2 mg/day) were not included.
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Figure 1. Study design timeline. 
2.2. Randomization, Immunosuppression Protocol and Interventions 
After signing the informed consent, patients were randomized 1:1 at 3-months post-
transplantation, using a centralized interactive response system before the protocol-bi-
opsy, to 1 of 2 CS therapeutic protocols, CS continuation (CSC) and CSW. Both groups 
received the same immunosuppression for 3 months (CS, TAC plus MMF), followed by 
tapering CS over one month, until stopping in the CSW group for the remainder of the 
study. Briefly, study medication consisted of induction treatment (basiliximab or thymo-
globulin) according to the protocol of each participating center, plus 0.5 g methylpredni-
solone, intravenously and intraoperatively administered, with a quantity of 125 mg given 
on day 1; prednisone was administered at a quantity of 30 mg/day for the first four days, 
with gradual dose reduction until reaching 5 mg/day at the second month post-transplan-
tation. TAC (Prograf®® or Advagraf®®) was administered at 0.15 mg/kg p.o. per day to 
maintain trough levels of 8–12 ng/mL in the first month and, later, TAC 0.1 mg/kg/day 
(trough levels of 5–8 ng/mL), and MMF 2 g/day during the first 15 days post-transplanta-
tion and, later, MMF 1 g/day plus CS 5 mg/day p.o. during the rest of the study. The dose 
of MMF was adjusted as necessary. Neither patients nor clinicians were blinded to ther-
apy. 
2.3. Protocol Biopsies and Histological Assessment 
Protocol-biopsies were performed at 3- and 24-months post-transplant as an outpa-
tient procedure. All biopsies were conducted under ultrasound guidance using an 18 G 
spring-loaded biopsy needle. At least 1 core of tissue with a minimum of 7 glomeruli and 
1 artery were required for proper interpretation. SCI, including BL and isolated mild in-
flammation without tubulitis (IIF) (i1, t0), was defined as an interstitial inflammation score 
(i) and/or tubulitis score (t) of at least 1, but below the threshold for Banff 1A rejection 
(Banff i2, t2) [5]. The chronic allograft histology score was obtained using a composite of 
chronic interstitial (ci), chronic tubular (ct), chronic glomerular (cg) plus chronic vascular 
(cv) (ci + ct + cg + cv) measures, as well as using a composite of interstitial fibrosis and 
tubular atrophy (IFTA) score (ct + ci). IFTA was defined as the sum of ci + ct ≥ 2. We eval-
uated the proportion of SCI in both groups and compared the chronic allograft histology 
score and IFTA score between the groups. Experienced transplant pathologists in each 
center interpreted all biopsies, and scores were all validated by a single pathologist (ML). 
We also assessed the biopsy-proven acute rejection (BPAR) rate during the study in 
both groups of patients according to the Banff 2015 criteria [5]. Clinical and subclinical 
BPAR were initially treated with three boluses of 500 mg intravenous methylpredniso-
lone. Corticoresistant rejection was treated with rabbit thymoglobulin. ABMR was treated 
with 3 boluses of methylprednisolone and plasmapheresis, plus intravenous Ig and/or 
Figure 1. Study design timeline.
All patients gave informed consent, and the study was approved by the ethics and clin-
ical research committee of each participating center, and by the Spanish Drug Agency (Eu-
draCT 2012-003298-24). The study followed the principles of the Declarations of Helsinki
and Istanbul.
2.2. Randomization, Immunosuppression Protocol and Interventions
After signing the informed consent, pat ents were randomized 1:1 at 3-months post-
ransplantation, using a centralized interactive response sys em before the protocol-biopsy,
t 1 of 2 CS therapeutic prot c ls, CS continuation (CSC) a d CSW. Both groups rec ived
the same immunosuppression for 3 months (CS, TAC plus MMF), followed by tapering
CS over one month, until stopping in the CSW gr up for the remainder of the study.
Briefly, st dy medication consisted of induction treatment (basilixi ab or thymoglobulin)
ccording to the protocol of each participating center, plus 0. g methylprednisolone,
intrave ously and intraoperatively administered, with a quantity of 125 mg given on day 1;
prednisone was administered at a quantity of 30 mg/day for the first four days, with
gradual dose reduction until reaching 5 mg/day at the second month post-transplantation.
TAC (Prograf®® or Advagraf®®) was administered at 0.15 mg/kg p.o. per day to maintain
trough levels of 8–12 ng/mL in the first month and, later, TAC 0.1 mg/kg/day (trough
levels of 5–8 ng/mL), and MMF 2 g/day during the first 15 days post-transplantation and,
later, MMF 1 g/day plus CS 5 mg/day p.o. during the rest of the study. The dose of MMF
was adjusted as necessary. Neither patients nor clinicians were blinded to therapy.
2.3. Protocol Biopsies and Histological Assessment
Protocol-biopsies were performed at 3- and 24-months post-transplant as an outpatient
procedure. All biopsies were conducted under ultrasound guidance using an 18 G spring-
loaded biopsy needle. At least 1 core of tissue with a minimum of 7 glomeruli and 1 artery
were required for proper interpretation. SCI, including BL and isolated mild inflammation
without tubulitis (IIF) (i1, t0), was defined as an interstitial inflammation score (i) and/or
tubulitis score (t) of at least 1, but below the threshold for Banff 1A rejection (Banff i2, t2) [5].
The chronic allograft histology score was obtained using a composite of chronic interstitial
(ci), chronic tubular (ct), chronic glomerular (cg) plus chronic vascular (cv) (ci + ct + cg +
cv) measures, as well as using a composite of interstitial fibrosis and tubular atrophy (IFTA)
score (ct + ci). IFTA was defined as the sum of ci + ct ≥ 2. We evaluated the proportion
of SCI in both groups and compared the chronic allograft histology score and IFTA score
between the groups. Experienced transplant pathologists in each center interpreted all
biopsies, and scores were all validated by a single pathologist (ML).
We also assessed the biopsy-proven acute rejection (BPAR) rate during the study in
both groups of patients according to the Banff 2015 criteria [5]. Clinical and subclinical
BPAR were initially treated with three boluses of 500 mg intravenous methylprednisolone.
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Corticoresistant rejection was treated with rabbit thymoglobulin. ABMR was treated
with 3 boluses of methylprednisolone and plasmapheresis, plus intravenous Ig and/or
rituximab. SCI or BL did not receive CS boluses. We also evaluated the proportion of SCI
in both groups and compared the chronic allograft histology score and IFTA score between
the groups.
Universal pneumocystis jirovecii prophylaxis was administered with cotrimoxazol,
and anti-cytomegalovirus prophylaxis in at-risk patients according to the schedule of each
participating center.
2.4. Testing for dnDSA
HLA antibodies were checked by One Lambda LAB screen single antigen bead as-
say. Background normalized mean fluorescent intensity (MFI) was established for each
dnDSA. A MFI value > 500 U was considered significant. The cut off of 500 U was defined
according to previous studies exploring relationships between SCI and DSA generation [7].
We checked dnDSA at 1-, 3-, 6-, 12- and 24-months post-KT. Post-transplant dnDSA ≥ 500 U
were considered positive.
2.5. Cardiovascular and Renal Assessment
Patients were monitored weekly during the first month and at 3-, 12- and 24-months
post-KT to assess efficacy and safety. The glomerular filtration rate was estimated by
MDRD-4 (e-GFR), and proteinuria was quantified either in 24-h urine or as the pro-
tein:creatinine ratio in the first voided morning sample. We also evaluated cardiovascular
risk factors such as blood pressure, lipid profile and post-transplant diabetes mellitus
(PTDM), diagnosed with the American Diabetes Association criteria [14]. Finally, we as-
sessed graft and patient survival. All adverse events were monitored and recorded.
2.6. Statistical Analysis
Efficacy and safety analyses were performed by both intention-to-treat and per-
protocol. Quantitative variables are expressed as the mean ± standard deviation or as
median and interquartile range (IQR), and qualitative variables as percentages. Statistical
analysis was started by comparing the two study groups. Inter-group comparisons of
quantitative variables were performed by Student t test or the Mann–Whitney U-test as
appropriate. Categorical variables were compared using the chi-square test or Fisher’s
exact test. Analysis of variance or the Kruskal–Wallis test was used to compare contin-
uous variables throughout the study. The Bonferroni procedure was used for multiple
comparisons. Graft and patient survival were assessed using the Kaplan–Meier method
and log-rank test, as well as the cumulative incidence of acute rejection. Analyses were
conducted with SPSS 20.0 (IBM SPSS statistic). A p value <0.05 was considered significant.
3. Results
3.1. Baseline Clinical and Histological Data
Table 1 shows baseline demographic-clinical characteristics in both groups at the time
of randomization. Clinical data were comparable except for the greater prevalence of
pre-transplant diabetes and adult polycystic kidney disease in the CSC group, whereas the
CSW group had more interstitial nephropathy. Although non-significant, a trend toward a
higher e-GFR and HbA1c levels was also observed in the CSC group versus the CSW group.
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Table 1. Baseline clinical data at the time of randomization (3-months post-transplant).
CSC (n = 52) CSW (n = 53) p
Donor age (years) 52.7 ± 13 54.7 ± 12 0.403
ECD (%) 36.5 47 0.270
Living donor (%) 13.5 15.7 0.787
Recipient weight (kg) 78.3 ± 13 74.7 ± 17 0.338
Recipient BMI
(kg/m2) 27 ± 4.1 25.7 ± 4.2 0.211
Male (%) 72 75 0.826
Prior CVD (%) 27 11.3 0.050
Hemodialysis (%) 71 65.4 0.664













(h) 10.4 ± 6 11 ± 6.4 0.640
Pretransplant PRA
(%) 1.7 ± 6.6 1.2 ± 5.1 0.653
Glycemia (mg/dL) 119.9 ± 66 102.7 ± 23 0.088
HbA1c % 6.3 ± 1.5 5.7 ± 0.8 0.070
Total cholesterol
(mg/dL) 171.3 ± 30.5 175.2 ± 40 0.609
HDL-cholesterol
(mg/dL) 48.2 ± 13.3 47.2 ± 10 0.698
LDL-cholesterol
(mg/dL) 95.6 ± 26 99.4 ± 29.4 0.532
Triglycerides
(mg/dL) 139.3 ± 57 152 ± 10.4 0.478
Hypertension (%) 90.2 90.4 1.000
SBP (mmHg) 131 ± 17 130.5 ± 16 0.861
DBP (mmHg) 72.6 ± 9.7 75.5 ± 8 0.133
Tacrolimus levels
(ng/mL) 9.8 ± 2.7 8.9 ± 2.2 0.081
MMF dose (mg) 1029 ± 314 1102 ± 297 0.253
Total HLA
mismatches * (n) 6.2 ± 2.2 6.1 ± 2.3 0.763
Proteinuria (mg/dL) 286.3 ± 214 286.1 ± 238 0.998
MDRD-4 (mL/min) 57.6 ± 22 50.4 ± 16.4 0.064
APKD, adult polycystic kidney disease; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic
blood pressure; ECD, expanded criteria donor; ESRD, end-stage renal disease; HDL, high-density lipoprotein;
HLA, human leucocyte antigen; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease 4
variable for estimating glomerular filtration rate; PRA, panel reactive antibodies; SBP, systolic blood pressure;
CSC, corticosteroid continuation; CSW, corticosteroid withdrawal. * Includes HLA-ABC-DR-DQ mismatching.
Non-significant differences were found in acute or chronic histological scores between
groups at the 3-month protocol-biopsy (Table 2).
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Table 2. Banff scores in the baseline protocol biopsy at 3-months post-transplant.
CSC (n = 52) CSW (n = 53) p
g (0–3) 0.04 ± 0.2 0.07 ± 0.3 0.444
ptc (0–3) 0.06 ± 0.2 0.16 ± 0.4 0.158
t (0–3) 0.3 ± 0.46 0.36 ± 0.48 0.533
i (0–3) 0.48 ± 0.5 0.53 ± 0.5 0.628
v (0–3) 0 0.02 ± 0.14 0.322
ci (0–3) 0.36 ± 0.48 0.46 ± 0.5 0.302
ct (0–3) 0.28 ± 0.46 0.41 ± 0.5 0.175
cg (0–3) 0 0
cv (0–3) 0.4 ± 0.6 0.36 ± 0.5 0.716
ah (0–3) 0.36 ± 0.6 0.34 ± 0.6 0.865
ct + ci 0.63 ± 0.9 0.86 ± 0.92 0.206
IFTA ≥ 2 (%) 32.6 39 0.535
ct + ci + cg + cv 1.04 ± 1.24 1.22 ± 1.11 0.451
Abbreviations: ah, arteriolar hyaline thickening; ci, chronic interstitial fibrosis; cg, transplant glomerulopathy; ct,
chronic tubular; cv, fibrous intimal thickening; g, glomerulitis; i, interstitial infiltration; ptc, peritubular capilaritis;
t, tubulitis; v, arteritis; CSC, corticosteroid continuation; CSW, corticosteroid withdrawal; IFTA: proportion of
patients with sum of interstitial fibrosis and tubular atrophy ≥ 2.
3.2. Acute Rejection during Follow-Up
A total of 24 patients had BPAR after randomization, of whom only 4 were clinically
suspected and 20 were subclinical rejections (15 BL, 4 TCMR and 1 ABMR), detected at the
24-month protocol-biopsy (Table 3). Additionally, 14 patients (CSC, n = 10 and CSW, n = 4)
showed IIF.
Table 3. Rejection episodes occurring after randomization.
Rejection CSC (n = 52) CSW (n = 53)




TCMR IA 0 2
TCMRIB 1 1
ABMR 1 0




Abbreviations: TCMR, T-cell-mediated rejection; ABMR, antibody-mediated rejection; CSC, corticosteroid contin-
uation; CSW, corticosteroid withdrawal.
3.3. Histological Data Evolution
A total of 51 patients showed NI and 54 presented SCI (including IIF, n = 22) at the
baseline 3-month biopsy. As expected, when we compared patients with SCI and NI,
a higher acute inflammation score and chronicity score were seen in patients with SCI
despite a comparable delayed graft function rate (defined as the need for dialysis during
the first week post-transplantation), percentage of expanded criteria donors and TAC
trough levels (Table 4), as well as a significant correlation between inflammatory and
chronicity scores (r = 0.247; p = 0.005). Likewise, the SCI patients had significantly more
HLA mismatches. Accordingly, a significantly better GFR was observed in the NI group.
Similar acute and chronic histological changes were observed between patients with NI
and SCI in the CSC and CSW groups (Table S1).
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Table 4. Inflammatory and chronicity scores and clinical data in the NI and SCI groups at the baseline
3-month protocol biopsy.
NI (n = 51) SCI (n = 54) p
g (0–3) 0.02 ± 0.15 0.09 ± 0.29 0.122
ptc (0–3) 0 0.21 ± 0.46 0.002
t (0–3) 0 0.63 ± 0.49 0.000
i (0–3) 0 0.96 ± 0.19 0.000
v (0–3) 0 0.02 ± 0.14 0.357
ci (0–3) 0.29 ± 0.46 0.58 ± 0.49 0.004
ct (0–3) 0.25 ± 0.44 0.51 ± 0.51 0.009
cg (0–3) 0 0
cv (0–3) 0.27 ± 0.45 0.53 ± 0.62 0.023
ah (0–3) 0.29 ± 0.58 0.41 ± 0.63 0.339
ct + ci 0.52 ± 0.88 1.06 ± 0.93 0.005
IFTA ≥2 (%) 25 45.8 0.037
ct + ci + cg + cv 0.76 ± 1.03 1.60 ± 1.20 0.001
ECD (%) 36 49 0.181
DGF (%) 24 27 0.735
Creatinine (mg/dL) 1.4 ± 0.5 1.6 ± 0.4 0.018
Proteinuria (mg/dL) 297 ± 229 279 ± 225 0.763
MDRD (mL/min) 60.0 ± 23.4 48.5 ± 13.6 0.003
Total HLA mismatches * (n) 5.4 ± 2.4 6.9 ± 2.0 0.002
Tacrolimus levels (ng/mL) 9.7 ± 2.9 9.2 ± 2.1 0.286
Abbreviations: ah, arteriolar hyaline thickening; ci, chronic interstitial fibrosis; cg, transplant glomerulopathy; ct,
chronic tubular; cv, fibrous intimal thickening; g, glomerulitis; i, interstitial infiltration; ptc, peritubular capilaritis;
t, tubulitis; v, arteritis; DGF, delayed graft function; ECD, expanded criteria donor; MDRD, modification of
diet in renal disease 4 variable for estimating glomerular filtration rate; NI, no inflammation; SCI, subclinical
inflammation; IFTA: proportion of patients with sum of interstitial fibrosis and tubular atrophy ≥ 2. * Includes
HLA-ABC-DR-DQ mismatching.
Changes in acute inflammatory score from 3 to 24 months in both the NI and SCI
groups are displayed in Figure 2. At 24 months, only 30.8% of SCI patients remained free of
inflammation, whereas this occurred in 22.2% of NI patients. Additionally, no differences
were observed in inflammatory or chronic lesion scores between groups at the 24-month
protocol biopsy (Table 5). Overall changes in both acute inflammatory and chronicity scores
from 3 to 24 months in patients with NI and patients with SCI, regardless of treatment,
are presented in Table 6. Details of the individual inflammatory and chronicity scores
in the two groups are outlined in Table S2. At 24-months post-transplant, an increase in
chronicity scores (IFTA and global chronicity score) was observed in patients with baseline
(3rd month) NI and SCI in both study groups. This was more evident in the CSW group
when patients with a lower baseline degree of inflammation (IIF) were excluded (n = 22)
from the analysis (Figure 3).




Figure 2. Evolution of histological data from 3 to 24 months. Patients with acute inflammation at 
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ct + ci 1.21 ± 1.13 1.76 ± 1.54 0.144 
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Figure 3. Changes in chronicity scores from 3 to 24 months in both study groups in patients with 
SCI at the 3-month protocol biopsy, excluding patients with isolated mild inflammation without 
tubulitis (i1, t0) (n = 22). 
3.4. De Novo DSA 
Using an MFI cut-off of > 500 U, it was found that no patients developed dnDSA at 
24 months. Likewise, the occurrence of non-dnDSA was similar in both groups at study 
end (CSC, 3.2 vs. CSW, 3.4%). 
3.5. Clinical and Biochemical Data 
Although non-significant differences were observed in the proportion of PTDM be-
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Table 6. Overall changes in both acute inflammatory and chronicity scores from 3 to 24 months in
patients with NI (n = 36) and SCI (n = 39) at the 3-month protocol biopsy.
NI SCI
Month 3 Month 24 p Month 3 Month 24 p
g (0–3) 0.04 ± 0.21 0.26 ± 0.45 0.057 0.09 ± 0.30 0.03 ± 0.18 0.325
ptc (0–3) 0 0.43 ± 0.73 0.009 0.19 ± 0.40 0.06 ± 0.25 0.103
t (0–3) 0 0.55 ± 0.59 0.000 0.56 ± 0.50 0.50 ± 0.67 0.645
i (0–3) 0 0.74 ± 0.62 0.000 0.97 ± 0.18 0.75 ± 0.76 0.109
v (0–3) 0 0 0 0
ci (0–3) 0.25 ± 0.44 0.80 ± 0.83 0.017 0.55 ± 0.51 0.79 ± 0.62 0.070
ct (0–3) 0.20 ± 0.41 0.80 ± 0.77 0.010 0.48 ± 0.51 0.79 ± 0.61 0.036
cg (0–3) 0 0.20 ± 0.52 0.104 0 0
cv (0–3) 0.17 ± 0.38 0.56 ± 0.71 0.049 0.61 ± 0.63 0.61 ± 0.79 1
ah (0–3) 0.23 ± 0.53 0.68 ± 0.89 0.038 0.25 ± 0.44 0.50 ± 0.67 0.073
ct + ci 0.45 ± 0.83 1.6 ± 1.54 0.011 1.03 ± 0.94 1.59 ± 1.21 0.036
IFTA ≥ 2 (%) 25 54.5 0.625 45.8 59.4 0.244
ct + ci + cg + cv 0.67 ± 0.97 2.50 ± 1.72 0.001 1.68 ± 1.12 2.25 ± 1.38 0.088
ah, arteriolar hyaline thickening; ci, chronic interstitial fibrosis; cg, transplant glomerulopathy; ct, chronic tubular;
cv, fibrous intimal thickening; g, glomerulitis; i, interstitial infiltration; ptc, peritubular capilaritis; t, tubulitis; v,
arteritis; NI, no inflammation; SCI, subclinical inflammation. IFTA: proportion of patients with sum of interstitial
fibrosis and tubular atrophy ≥ 2.
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3.4. De Novo DSA
Using an MFI cut-off of > 500 U, it was found that no patients developed dnDSA at 24
months. Likewise, the occurrence of non-dnDSA was similar in both groups at study end
(CSC, 3.2 vs. CSW, 3.4%).
3.5. Clinical and Biochemical Data
Although non-significant differences were observed in the proportion of PTDM be-
tween groups (20.5 vs. 14.3%; p = 0.482), HbA1c levels were significantly lower in the CSW
group at 24 months (Table 7). Likewise, a lower systolic blood pressure was observed in
CSW patients at study end. No other differences were seen between groups, including
lipid profile, GFR, proteinuria, body mass index and TAC trough levels at 24-months
post-transplant (Table 7). Finally, a trend toward a higher mean MMF dosage was ad-
ministered in the CSW group compared with the CSC group during the first 12 months
post-transplantation.
Table 7. Clinical and biochemical data during follow up.
CSC n = 52 CSW n = 53 p Value
Weight (kg)
12 months 81.5 ± 13.4 78.0 ± 16.6 0.323
24 months 83.9 ± 14.3 81.4 ± 17.4 0.531
BMI (kg/m2)
12 months 28.6 ± 4.1 27.2 ± 4.7 0.181
24 months 29.9 ± 4.6 28.1 ± 4.8 0.162
HbA1c (%)
12 months 6.5 ± 1.5 5.7 ± 0.8 0.017
24 months 6.4 ± 1.2 5.7 ± 0.3 0.013
Glucose (mg/dL)
12 months 110.6 ± 38.1 106.3 ± 20.9 0.494
24 months 107.8 ± 26.5 112.3 ± 32.9 0.494
Total cholesterol
(mg/dL)
12 months 163.0 ± 30.4 149.2 ± 20.9 0.017
24 months 162.7 ± 26.7 165.2 ± 30.3 0.704
HDL-cholesterol
(mg/dL)
12 months 49.8 ± 15.2 42.0 ± 13.6 0.024
24 months 49.7 ± 14.0 44.6 ± 12.2 0.117
LDL-cholesterol
(mg/dL)
12 months 85.8 ± 23.9 80.4 ± 19.0 0.286
24 months 86.3 ± 19.7 95.1 ± 21.5 0.087
Triglycerides
(mg/dL)
12 months 137.2 ± 49.5 132.6 ± 63.9 0.717
24 months 137.5 ± 56.1 131.2 ± 73.1 0.681
SBP (mmHg)
12 months 133.4 ± 18.9 129.3 ± 14.8 0.278
24 months 134.2 ± 14.9 125.7 ± 15.3 0.016
DBP (mmHg)
12 months 75.2 ± 9.3 74.3 ± 10 0.709
24 months 74.5 ± 10.7 75.4 ± 8.8 0.699
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Table 7. Cont.
CSC n = 52 CSW n = 53 p Value
Tacrolimus levels
(ng/mL)
12 months 8.6 ± 2.8 7.9 ± 1.8 0.158
24 months 7.5 ± 2.5 7.3 ± 1.6 0.582
MMF Doses (mg)
12 months 937 ± 162 1005 ± 174 0.208
24 months 935 ± 156 909 ± 240 0.570
Creatinine (mg/dL)
12 months 1.4 ± 1.0 1.5 ± 0.5 0.714
24 months 1.3 ± 0.4 1.5 ± 0.4 0.133
Proteinuria (mg/24 h)
12 months 284.6 ± 288.0 172.2 ± 144.5 0.075
24 months 512.5 ± 1306.5 160.4 ± 110.5 0.284
MDRD (mL/min)
12 months 59.1 ± 16.6 54.3 ± 18.0 0.171
24 months 60.1 ± 18.2 55.4 ± 19.5 0.235
BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; HLA, human leucocyte
antigen; LDL, low-density lipoprotein; MDRD, modification of diet in renal disease 4 variable for estimating
glomerular filtration rate, estimated by formulae from modification of diet in renal disease; SBP, systolic blood
pressure; CSC, corticosteroid continuation; CSW, corticosteroid withdrawal.
3.6. Safety and Graft and Patient Survival
Table 8 summarizes the serious adverse events in both groups. Forty-seven adverse
events were detected in 44 patients. Paradoxically, there was a trend toward a higher
number of patients with severe infections requiring hospitalization in the CSW group.
In particular, three CSW patients had two severe infections. All infections resolved suc-
cessfully with targeted treatment. In addition, five patients suffered ischemic heart disease
(CSC, n = 3 and CSW, n = 2) but were satisfactorily revascularized. Finally, three malignan-
cies were documented: native kidney carcinoma in one CSC patient and two non-melanoma
skin cancers (one in each group). After randomization, no patients died or lost their grafts
during follow up in the intention-to-treat analysis.
Table 8. Serious adverse events during the follow up.
CSC n = 52 CSW n = 53 p Value
Urinary sepsis, n (%) 1 (1.9) 2 (3.8) 0.569
CMV infection, n (%) 3 (5.7) 8 (15) 0.191
BK virus infection, n (%) 1 (1.9) 6 (11.3) 0.108
Patients with any serious
infection * (%) 5 (9.6) 13 (24.5) 0.070
Cardiovascular disease, n (%) 3 (5.7) 2 (3.8) 0.677
Neoplasia, n (%) 2 (3.8) 1 (1.9) 0.618
CMV, cytomegalovirus. * Infections requiring hospitalization. CSC, corticosteroid continuation; CSW, corticos-
teroid withdrawal.
4. Discussion
This randomized controlled study shows that although increased chronicity scores at
2-years post-transplantation were observed in low-immunological-risk KT recipients with
initial (3rd month) NI or SCI irrespective of treatment, CSW at that time may accelerate
chronicity changes, especially in patients with early SCI (e.g., BL). Nevertheless, this
strategy improved the cardiovascular profiles of patients, which might prolong their long-
term survival.
CS have been a mainstay of immunosuppression in KT for > 60 years. CS suppress
B-cell antibody production as the result of altered T-cell function on allogenic B-cell activa-
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tion [15]. As a consequence, an increased risk of acute rejection (clinical and subclinical)
was related to CSW in a recent meta-analysis [4], but this does not seem to significantly
affect graft survival, especially when complete functional recovery is achieved or when
CSW is performed 3–6-months post-transplantation in low-to-moderate-immune risk KT
recipients under TAC-based immunosuppression [16]. Rejection rates in our study were
comparable in both groups, but we cannot discard the possibility that a larger sample or
longer follow-up could yield significant differences in immunological dysfunction rate
between groups. Nevertheless, TAC trough levels were comparable between patients with
and without CS and no dnDSA appeared throughout our study. In consonance with our
results, randomized clinical trials using modern immunosuppression showed no differ-
ences in acute rejection rates between patients with and without CS [3,17–19], suggesting
that this strategy could be feasible and safe in low-immunological risk patients under
TAC-based immunosuppression, provided that graft inflammation is not present at the
moment of CSW.
Several studies of early protocol biopsies have demonstrated that SCI exists in about
50% of allografts, indicating that inflammatory phenomena could perpetuate in shaping
chronic allograft changes [20,21]. However, the clinical impact of SCI on long-term KT
outcomes is not yet totally clarified, and data concerning the effect of CSW on inflamma-
tory or chronicity changes post-transplantation are lacking. While some authors found a
worse prognosis of SCI, evolving to histological chronic changes and allograft dysfunc-
tion [7,8,20,22–32], others did not, especially in patients not developing dnDSA and in those
with either isolated tubulitis (t > 0, i0) or inflammation (t0, i > 0); thus, these histological find-
ings are currently questioned as a BL category [8,9,24,33–36]. Indeed, some studies failed to
show a significant association between early SCI and relevant IFTA [33,37,38], particularly
in studies including patients with IIF (i1, t0) [39]. Additionally, many biopsies interpreted
initially as BL by pathologists have later been found to be non-rejection by molecular phe-
notyping and suggestions have been made to eliminate the category altogether [40]. Seron
at al. found no differences in allograft function at one- and 2-years post-transplantation
between patients with and without SCI at 3-months post-transplantation [41]. Conversely,
others found an impaired GFR at 2-years post-transplantation in SCI patients compared
with normal biopsies [6,28,42]. Finally, a small randomized clinical trial, performed in
low-immunological-risk KT recipients under TAC-based immunosuppression, showed a
modest greater degree of fibrosis at 1 year in the CSW group, but more detailed informa-
tion on SCI was not provided [43]. Thus, whether CSW could accelerate chronic changes
remains uncertain.
We found SCI in a number of patients at 3- and 24-months post-transplant despite
induction therapy and stable GFR. As expected, we observed a higher inflammatory
score in SCI patients at 3 months and more total HLA mismatches compared with the NI
group regardless of treatment, which was globally associated with higher inflammatory
and chronicity scores at 24-months post-transplantation. In agreement with our results,
both HLA-DR and HLA-DQ mismatching have been related to SCI [44,45], and, overall,
patients with low-grade inflammation in protocol-biopsies obtained at 1–4-months post-
transplant have also shown more IFTA in successive biopsies [6,20,46]. Likewise, a higher
chronicity score at 24 months in our patients with initial NI (3rd month) was not surprising,
as has been reported in KT recipients with and without CSW [7,43,47]. Additionally,
at 24 months, an increase in inflammatory and chronicity scores was found in patients
with baseline (3rd month) NI and SCI in both study groups. Importantly, CSW patients
with SCI at 3-months post-transplant showed a significant increase in chronicity scores at
24 months compared with CSC patients, which was more evident when patients with IIF
were excluded. This suggests that CSW could have accelerated chronicity changes in these
patients. This could have contributed to a trend toward a better GFR in the CSC group
despite a similar BPAR rate and TAC levels at study end. Previous reports found an increase
in chronicity scores and a worse allograft function in patients with early (1–4 months post-
transplant) SCI one year after CSW, despite proper TAC levels [6,7,48]. The fact that non-use
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of CS was an independent determinant of IFTA at 1-year post-transplantation supports
these arguments [49]. Accordingly, we re-started steroids only in those in the CSW group
who presented SCI at the 24-month protocol biopsy and in those who had BPAR during
follow up.
Whether histological changes were present at the time of KT is unknown because no
routine donor biopsies were performed. However, no significant differences were found in
the percentage of expanded criteria donors between patients without inflammation and
those with SCI at the 3-month protocol biopsy. In addition, no significant differences in
the chronicity scores at the time of randomization (3rd month) were seen between the NI
and SCI groups in the subset of KT patients who received grafts from expanded criteria
donors (Table S3). Finally, patients from both groups without inflammation at 3-months
post-transplant showed progression of chronic lesions at the 24-month biopsy, though
likely for other reasons. Whether ischemia-reperfusion damage could have contributed to
these chronic changes is undetermined and was not part of this study.
Notably, CSW was not associated with the development of dnDSA in our patients
using a MFI cut-off ≥ 500 and, thus, no relationship between dnDSA and graft immuno-
logical lesions could be established. Consistent with our results, randomized and observa-
tional studies have found no differences in the development of dnDSA in patients with
or without CS using modern immunosuppression [50–52]. The appearance of dnDSA
in prospective studies ranged from 0 to 10% one-year post-transplantation under TAC
trough levels > 7 ng/mL [13,37,53]. In our study, mean TAC trough levels were around
7 ng/mL and comparable between groups throughout the study. Nevertheless, this find-
ing has to be interpreted with caution because the mean time to developing dnDSA
in low-immunological-risk KT recipients receiving conventional immunosuppression is
4 years [54], which makes the appearance of antibodies unlikely during the first 2 years
post-transplant, as occurred in our study. Whether a longer-term controlled study would
demonstrate the development of dnDSA is, as yet, undetermined.
Finally, a similar low proportion of patients in both groups developed de novo non-
dnDSA during the study, in agreement with previous reports [50]. This finding had no
negative impact on graft survival in our study. A longer post-transplant clinical follow-up
and testing for non-dnDSA will be needed to elucidate this concern.
CSW has been associated with improved graft and patient survival [3,55–57]. Ad-
ditionally, several studies examined the beneficial effects of CSW on cardiovascular risk
factors in KT recipients [19,57–61]. In particular, early and late CSW have been associated
with risk reduction of PTDM [57,59,60]. However, recent studies in KT recipients under
TAC therapy yielded conflicting results, suggesting that the beneficial role of CSW on
CS-induced diabetes under TAC-based immunosuppression is less clear [62–64]. Thus,
the diabetogenicity of TAC may have partially outweighed the beneficial effects of CSW
in PTDM incidence. We found no significant differences in PTDM between groups, but a
significant reduction in HbA1c was observed in the CSW group, suggesting that PTDM was
more manageable in these patients [64,65]. No oral glucose tolerance test to discard occult
diabetes was performed during follow up. We used the term PTDM to describe persistent
hyperglycemia post-transplant that was not present at the time of KT [66]. Whether a
reduction in HbA1c levels is associated with lower cardiovascular disease in KT recipients
remains unclear.
CSW is also related to better blood pressure control in KT recipients, with a reduction in
systolic pressure [57,58]. Similarly, a significant decrease in systolic pressure was observed
in the CSW group at 24 months despite a comparable body mass index, and comparable
TAC levels and GFR, between groups. Whether this translates into fewer cardiovascular
events or decreased mortality in the long-term remains to be clarified.
A trend toward a higher number of infections was observed in the CSW group despite
these patients not receiving CS. This may have been because these patients received a
higher dosage of MMF during the first twelve months post-transplantation and, thus,
had a greater mycophenolic acid toxicity, which is associated with an increased risk of
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infectious complications post-transplantation. This potential performance bias could be a
consequence of the open-label design of our study.
This study has some limitations. It could be underpowered to demonstrate the ob-
served non-inferiority between groups in terms of acute rejection rate. Thus, comparison
between the CSC and CSW groups should be cautious. In addition, we studied Caucasian
and low-immunological-risk KT patients with an acceptable-functioning graft, so the re-
sults are not representative of other KT populations. However, major strengths include
the design of a randomized, controlled, prospective study in patients under modern TAC-
based immunosuppression, who underwent protocol 3-month and 2-year graft biopsies
with rigorous and timely follow-up of allograft function and detection of dnDSA using a re-
strictive MFI cut-off. An important number of patients in both groups had SCI at 3-months
post-transplant but received no specific treatment. However, important histological infor-
mation was obtained in patients with early SCI after CSW, rising to a higher chronicity
score at study end. We believe this is the first clinical trial to compare the evolution of SCI
in low-immunological-risk KT patients with and without CS.
5. Conclusions
In conclusion, an increasing chronicity score in the medium-term was observed in low-
immunological-risk KT patients with initial NI or SCI regardless of treatment. Nevertheless,
CSW may precipitate chronicity changes, mainly in patients with early (3rd month) SCI
such us BL. Finally, a better cardiovascular profile may be achieved with this strategy in
these patients.
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